Gernert, Michael http://orcid.org/0000-0003-0074-4459
Schmalzing, Marc http://orcid.org/0000-0002-3289-2299
Tony, Hans-Peter
Strunz, Patrick-Pascal http://orcid.org/0000-0002-3168-7074
Schwaneck, Eva Christina http://orcid.org/0000-0003-1935-2092
Fröhlich, Matthias http://orcid.org/0000-0001-7745-3903
Funding for this research was provided by:
Universitätsklinikum Würzburg
Article History
Received: 10 May 2022
Accepted: 21 July 2022
First Online: 19 August 2022
Declarations
:
: This study was a retrospective cohort study, why approval by the local ethics committee of the University of Würzburg was not mandatory. Solely routine parameters (for a tertiary referral center) were implemented in this analysis, why obtaining informed consent was not necessary according to German law. All data was generated in compliance with the declaration of Helsinki.
: Not applicable.
: MG received travel grants, compensation for advisory boards, or speaker’s fees from AbbVie, Chugai, Eli Lilly, Hexal, Janssen, Novartis, Pfizer, and Takeda.MS received speaker’s fees, travel grants, research funding, or compensation for consultancies or board memberships from AbbVie, Actelion, AstraZeneca, BMS, Boehringer/Ingelheim, Celgene, Chugai/Roche, Eli Lilly, Genzyme, Gilead, Hexal/Sandoz, Janssen-Cilag, MSD, Novartis, Pfizer, Sanofi Pasteur, Takeda (Shire), and UCB.H-PT received speaker’s fees, travel grants, research funding, or compensation for consultancies or board memberships from AbbVie, BMS, Chugai/Roche, Eli Lilly, Gilead, Janssen, Novartis, Sandoz/Hexal, Sanofi Aventis, and Takeda (Shire).P-PS received travel grants from AbbVie and Janssen-Cilag and research founding from Chugai.ECS received speaker’s fees, travel grants, research funding, or compensation for consultancies or board memberships from AbbVie, Amgen, Chugai, Eli Lilly, Galapagos, Janssen-Cilag, Novartis, Pfizer, Roche, and Takeda (Shire).MF received speaker’s fees, travel grants, or compensation for board memberships from AbbVie, Novartis, Janssen, and Eli Lilly.